PDF herunterladen
Semin Respir Crit Care Med 2021; 42(02): 316-326
DOI: 10.1055/s-0041-1722992
Review Article

COVID-19 and Its Implications for Thrombosis and Anticoagulation

Samuel A. Berkman
1   Department of Medicine, University of California Los Angeles, Hematology/Oncology, Los Angeles, California
,
Victor F. Tapson
2   Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19) coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be hospitalized, should receive at least prophylactic dose anticoagulation. However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence.

Keywords

COVID-19 - SARS-CoV2 - thrombosis - deep venous thrombosis - pulmonary embolism - anticoagulation - inflammation - hypercoagulability - prothrombotic


Publikationsverlauf

Artikel online veröffentlicht:
06. Februar 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011; 52 (02) e14-e17
    CrossrefPubMedGoogle Scholar
  • 2 Avnon LS, Munteanu D, Smoliakov A, Jotkowitz A, Barski L. Thromboembolic events in patients with severe pandemic influenza A/H1N1. Eur J Intern Med 2015; 26 (08) 596-598
    CrossrefPubMedGoogle Scholar
  • 3 Chong PY, Chui P, Ling AE. et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004; 128 (02) 195-204
    CrossrefPubMedGoogle Scholar
  • 4 Lew TWK, Kwek T-K, Tai D. et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003; 290 (03) 374-380
    CrossrefPubMedGoogle Scholar
  • 5 Who Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5: 5
    PubMedGoogle Scholar
  • 6 Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol 2011; 12 (09) 1481-1496
    CrossrefPubMedGoogle Scholar
  • 7 Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets?. Keio J Med 2005; 54 (03) 142-149
    CrossrefPubMedGoogle Scholar
  • 8 Finigan JH. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res 2009; 77 (01) 35-38
    CrossrefPubMedGoogle Scholar
  • 9 Panigada M, Bottino N, Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18 (07) 1738-1742
    CrossrefPubMedGoogle Scholar
  • 10 Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. Front Pediatr 2018; 6: 142
    Google Scholar
  • 11 Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence?. Int Immunopharmacol 2015; 28 (01) 655-665
    CrossrefPubMedGoogle Scholar
  • 12 Zeng F, Huang Y, Guo Y. et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis 2020; 96: 467-474
    CrossrefPubMedGoogle Scholar
  • 13 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 14 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 15 Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (06) 1421-1424
    CrossrefPubMedGoogle Scholar
  • 16 Modigliani C, Iapichino G, Carenzo L. Venous and arterial thromboembolic complications and COVID-19 patients admitted to an academic hospital in Milan, Italy. J Thromb Res 2020; 4: 24
    PubMedGoogle Scholar
  • 17 Liang W, Liang H, Ou L. et al; China Medical Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020; 180 (08) 1081-1089
    CrossrefPubMedGoogle Scholar
  • 18 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; 173 (04) 268-277
    CrossrefPubMedGoogle Scholar
  • 19 The American Society of Hematology. COVID-19 resources. . Accessed January 13, 2021 at: https://www.hematology.org/covid-19
    Google Scholar
  • 20 Spyropoulos AC, Levy JH, Ageno W. et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1859-1865
    CrossrefPubMedGoogle Scholar
  • 21 Barnes G, Burnett A. et al. Thromboembolism and anticoagulation treatment during the COVID 1 pandemic interim guidelines from the Anticoagulation Forum. Thromb Thrombolysis 2020
    Google Scholar
  • 22 Llitjos JF, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18 (07) 1743-1746
    CrossrefPubMedGoogle Scholar
  • 23 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
    CrossrefPubMedGoogle Scholar
  • 24 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
    CrossrefPubMedGoogle Scholar
  • 25 Pesavento R, Ceccato D, Pasquetto G. et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19: The Padua province experience. J Thromb Haemost 2020; 18 (10) 2629-2635
    CrossrefPubMedGoogle Scholar
  • 26 Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med 2020; 48 (09) 1358-1364
    CrossrefPubMedGoogle Scholar
  • 27 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis and angiogenesis in COVID 19. N Engl J Med 2020; 383 (02) 120-128
    CrossrefPubMedGoogle Scholar
  • 28 Lax SF, Skok K, Zechner P. et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 2020; 173 (05) 350-361
    CrossrefPubMedGoogle Scholar
  • 29 Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19?. JAMA Intern Med 2020; 180 (09) 1152-1154
    CrossrefPubMedGoogle Scholar
  • 30 Rapkiewicz AV. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsyin COVID-19: A case series. E Clin Med 2020; 24: doi:10.1016/j.eclinm.2020.100434
    PubMedGoogle Scholar
  • 31 Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998; 104 (04) 381-385
    CrossrefPubMedGoogle Scholar
  • 32 Ortel TL, Erkan D, Kitchens CS. How I treat catastrophic thrombotic syndromes. Blood 2015; 126 (11) 1285-1293
    CrossrefPubMedGoogle Scholar
  • 33 Lee DW, Gardner R, Porter DL. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124 (02) 188-195
    CrossrefPubMedGoogle Scholar
  • 34 Paranjpe I, Fuster V, Lala A. et al. An association with treatment dose anticoagulation with in-hospital survival among hospitalized patient with COVID-19. J Am Coll Cardiol 2020; 76 (01) 122-124
    CrossrefPubMedGoogle Scholar
  • 35 Moore HB, Barrett CD, Moore EE. et al. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?. J Trauma Acute Care Surg 2020; 88 (06) 713-714
    CrossrefPubMedGoogle Scholar
  • 36 Wang J, Hajizadeh N, Moore EE. et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 2020; 18 (07) 1752-1755
    CrossrefPubMedGoogle Scholar
  • 37 Gram J, Munster AM, Dilling-Hansen B. et al. Inhalation/intravenous recombinant tissue plasminogen activator and inhaled heparin in a patient with acute respiratory distress. syndrome. Fibrinolysis Proteolysis 1999; 13 (4,5): 209-212
    CrossrefPubMedGoogle Scholar
  • 38 Neumann I, Izcovich A, Zhang Y. et al. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv 2020; 4 (07) 1512-1517
    CrossrefPubMedGoogle Scholar
  • 39 Raskob GE, Spyropoulos AC, Cohen AT. et al. Increased risk of death in acutely ill medical patients with asymptomatic proximal deep vein thrombosis or symptomatic venous thromboembolism: insights from the MAGELLAN study. Blood 2019; 134 (01) 163
    CrossrefPubMedGoogle Scholar
  • 40 Kalayci A, Gibson CM, Chi G. et al. Asymptomatic deep vein thrombosis is associated with an increased risk of death: insights from the APEX trial. Thromb Haemost 2018; 118 (12) 2046-2052
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Cohen A, Spiro T, Buller H. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
    CrossrefPubMedGoogle Scholar
  • 42 Cohen AT, Harrington RA, Goldhaber SZ. et al; APEX Investigators. Extended thromboprophylaxis with Betrixaban in acutely ill medical patients. N Engl J Med 2016; 375 (06) 534-544
    CrossrefPubMedGoogle Scholar
  • 43 Spyropoulos AC, Ageno W, Albers GW. et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379 (12) 1118-1127
    CrossrefPubMedGoogle Scholar
  • 44 Engelen M. Low incidence of venous thromboembolism in patients discharged after COVID-19 hospitalization. Presented at ISTH 2020. . Virtual Congress; July 12–14; LC/CO01.3
    Google Scholar
  • 45 Roberts LN, Whyte MB, Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 2020; 136 (11) 1347-1350
    CrossrefPubMedGoogle Scholar
  • 46 Patell R, Bogue T, Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020; 136 (11) 1342-1346
    CrossrefPubMedGoogle Scholar
  • 47 Goldhaber SZ, Leizorovicz A, Kakkar AK. et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365 (23) 2167-2177
    CrossrefPubMedGoogle Scholar
  • 48 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 49 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 50 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med 2020; 382 (17) e38
    CrossrefPubMedGoogle Scholar
  • 51 Akhter E. IgG and IGA Beta2-GPI are associated with venous thrombosis in SLE. J Rheumatol 2013; 40: 2382-2386
    PubMedGoogle Scholar
  • 52 Dominguez V, Magder LS, Petri M. Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med Lupus Sci Med 2016; 3 (01) e000107
    CrossrefPubMedGoogle Scholar
  • 53 Oxley TJ, Mocco J, Majidi S. et al. Large vessel stroke as a presenting feature of Covid19 in the young. N Engl J Med 2020; 382 (20) e60
    CrossrefPubMedGoogle Scholar
  • 54 Fara MG, Stein LK, Skliut M, Morgello S, Fifi JT, Dhamoon MS. Macrothrombosis and stroke in patients with mild COVID-19 infection. J Thromb Haemost 2020; 18 (08) 2031-2033
    CrossrefPubMedGoogle Scholar
  • 55 Singhal AB, Gonzalez RG, Chwalisz BK, Mukerji SS. Case 26-2020: A 60-year-old woman with altered mental status and weakness on the left side. N Engl J Med 2020; 383 (08) 764-773
    CrossrefPubMedGoogle Scholar
  • 56 Bowles L, Platton S, Yartey N. et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID 19. N Engl J Med 2020; 383 (03) 288-290
    CrossrefPubMedGoogle Scholar
  • 57 Bellosta R, Luzzani L, Natalini G. et al. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg 2020; 72 (06) 1864-1872
    CrossrefPubMedGoogle Scholar
  • 58 Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20 (02) 119-122
    CrossrefPubMedGoogle Scholar
  • 59 Xu X, Han M, Li T. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117 (20) 10970-10975
    CrossrefPubMedGoogle Scholar
  • 60 Alattar R, Ibrahim TBH, Shaar SH. et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020; 92 (10) 2042-2049
    CrossrefPubMedGoogle Scholar
  • 61 Guaraldi G, Meschiari M, Cozzi-Lepri A. Tocilizumab in patients with severe COVID-19: a retrospectivecohort study. Lancet Rheumatol 2020; 2 (08) e474-e484
    Google Scholar
  • 62 Biot C, Daher W, Chavain N. et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006; 49 (09) 2845-2849
    CrossrefPubMedGoogle Scholar
  • 63 Schmidt-Tanguy A, Voswinkel J, Henrion D. et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013; 11 (10) 1927-1929
    CrossrefPubMedGoogle Scholar
  • 64 Petri MA, Conklin J, O'Malley T, Dervieux T. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Lupus Sci Med 2019; 6 (01) e000318
    CrossrefPubMedGoogle Scholar
  • 65 Pierangeli S, Vega-Ostertag M, Harris EN. et al. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. J Thromb Res 2004; 114 (5,6): 467-476
    CrossrefPubMedGoogle Scholar
  • 66 Rand JH, Wu X, Quinn A. et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115 (11) 2292-2299
    CrossrefPubMedGoogle Scholar
  • 67 Boulware DR, Pullen MF, Bangdiwala AS. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 2020; 383 (06) 517-525
    CrossrefPubMedGoogle Scholar
  • 68 Wang Y, Zhang D, Guanhua D. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569-1578
    CrossrefPubMedGoogle Scholar
  • 69 Beigel JH, Tomashek KM, Dodd LE. et al; ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020; 383 (19) 1813-1826
    CrossrefPubMedGoogle Scholar
  • 70 Spinner CD, Gottlieb RL, Criner GJ. et al; GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324 (11) 1048-1057
    CrossrefPubMedGoogle Scholar
  • 71 McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. JAMA 2020; 324 (11) 1041-1042
    CrossrefPubMedGoogle Scholar
  • 72 Cao B, Wang Y, Wen D. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382 (19) 1787-1799
    CrossrefPubMedGoogle Scholar
  • 73 Testa S, Prandoni P, Paoletti O. et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost 2020; 18 (06) 1320-1323
    CrossrefPubMedGoogle Scholar
  • 74 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID 19 with convalescent plasma. JAMA 2020; 323 (16) 1582-1589
    CrossrefPubMedGoogle Scholar
  • 75 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117 (17) 9490-9496
    CrossrefPubMedGoogle Scholar
  • 76 Roback JD, Guarner J. Convalescent plasma to treat COVID 19 possibilities and challenges. JAMA 2020; 323 (16) 1561-1562
    CrossrefPubMedGoogle Scholar
  • 77 Li L, Zhang W, Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324 (05) 460-470
    CrossrefPubMedGoogle Scholar
  • 78 Joyner MJ, Senefeld JW, Klassen SA. et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020 DOI: 10.1101/2020.08.12.20169359
    Google Scholar
  • 79 Horby PW, Landray M. Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report. Accessed January 13, 2021 at: https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.full.pdf
    Google Scholar
  • 80 Ye Z, Wang Y, Colunga-Lozano LE. et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020; 192 (27) E756-E767
    CrossrefPubMedGoogle Scholar
  • 81 Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19. Accessed January 13, 2021 at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
    Google Scholar
  • 82 Preventing COVID-19 complications with low- and high-dose anticoagulation (COVID-HEP). Accessed January 13, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04345848
    Google Scholar
  • 83 A randomized trial of anticoagulation strategies in COVID-19. Accessed January 13, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04359277
    Google Scholar
  • 84 Hematology recommendations and dosage guidelines, COVID 19, version 8. Massachusetts General Hospital. April 30, 2020.
    Google Scholar
  • 85 Considerations in the prophylaxis and treatment of venous thromboembolism and COVID 19 patients. Community of the American Venous Forum. Covid 19. . Accessed March 3, 2021 at: http://veinforum.com/veinforum.com
    Google Scholar
  • 86 Bikdeli B, Madhavan M, Jiminez D. COVID 19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy and follow-up: JACC state-of-the-art review. 2020; 75 (23) 2950-2973
    PubMedGoogle Scholar